Cargando…
Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between Ma...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691069/ https://www.ncbi.nlm.nih.gov/pubmed/36421623 http://dx.doi.org/10.3390/healthcare10112299 |
_version_ | 1784836952783060992 |
---|---|
author | Umemura, Takumi Mutoh, Yoshikazu Mizuno, Takahito Hagihara, Mao Kato, Hideo Yamada, Tetsuya Ikeda, Yoshiaki Mikamo, Hiroshige Ichihara, Toshihiko |
author_facet | Umemura, Takumi Mutoh, Yoshikazu Mizuno, Takahito Hagihara, Mao Kato, Hideo Yamada, Tetsuya Ikeda, Yoshiaki Mikamo, Hiroshige Ichihara, Toshihiko |
author_sort | Umemura, Takumi |
collection | PubMed |
description | There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between March 2020 and April 2022 at Tosei General Hospital, Japan. Propensity score matching was performed between patients with eGFR ≤ 30 mL/min and eGFR >30 mL/min with remdesivir administration. The primary outcome was 30-day mortality after the first administration. Adverse events, including development of acute kidney injury (AKI), liver function disorder, anemia, and thrombocytopenia 48 h after the end of remdesivir administration, were evaluated. After propensity score matching, 23 patients were selected from each group. There were no differences in the 30-day mortality (risk ratio [RR] 1.00; 95% confidence interval [CI] 0.18–5.56). Development of AKI and liver function disorder was not statistically different between the two groups (RR 1.05; 95% CI 0.96–1.14 and RR 0.48; 95% CI 0.04–5.66, respectively). There was no trend toward a significant increase in adverse events in the eGFR < 30 mL/min group and severe renal dysfunction had little effect on the safety of remdesivir treatment. |
format | Online Article Text |
id | pubmed-9691069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96910692022-11-25 Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study Umemura, Takumi Mutoh, Yoshikazu Mizuno, Takahito Hagihara, Mao Kato, Hideo Yamada, Tetsuya Ikeda, Yoshiaki Mikamo, Hiroshige Ichihara, Toshihiko Healthcare (Basel) Brief Report There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between March 2020 and April 2022 at Tosei General Hospital, Japan. Propensity score matching was performed between patients with eGFR ≤ 30 mL/min and eGFR >30 mL/min with remdesivir administration. The primary outcome was 30-day mortality after the first administration. Adverse events, including development of acute kidney injury (AKI), liver function disorder, anemia, and thrombocytopenia 48 h after the end of remdesivir administration, were evaluated. After propensity score matching, 23 patients were selected from each group. There were no differences in the 30-day mortality (risk ratio [RR] 1.00; 95% confidence interval [CI] 0.18–5.56). Development of AKI and liver function disorder was not statistically different between the two groups (RR 1.05; 95% CI 0.96–1.14 and RR 0.48; 95% CI 0.04–5.66, respectively). There was no trend toward a significant increase in adverse events in the eGFR < 30 mL/min group and severe renal dysfunction had little effect on the safety of remdesivir treatment. MDPI 2022-11-17 /pmc/articles/PMC9691069/ /pubmed/36421623 http://dx.doi.org/10.3390/healthcare10112299 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Umemura, Takumi Mutoh, Yoshikazu Mizuno, Takahito Hagihara, Mao Kato, Hideo Yamada, Tetsuya Ikeda, Yoshiaki Mikamo, Hiroshige Ichihara, Toshihiko Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study |
title | Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study |
title_full | Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study |
title_fullStr | Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study |
title_full_unstemmed | Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study |
title_short | Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study |
title_sort | safety evaluation of remdesivir for covid-19 patients with egfr < 30 ml/min without renal replacement therapy in a japanese single-center study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691069/ https://www.ncbi.nlm.nih.gov/pubmed/36421623 http://dx.doi.org/10.3390/healthcare10112299 |
work_keys_str_mv | AT umemuratakumi safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT mutohyoshikazu safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT mizunotakahito safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT hagiharamao safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT katohideo safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT yamadatetsuya safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT ikedayoshiaki safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT mikamohiroshige safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy AT ichiharatoshihiko safetyevaluationofremdesivirforcovid19patientswithegfr30mlminwithoutrenalreplacementtherapyinajapanesesinglecenterstudy |